Previous 10 | Next 10 |
Xenetic Biosciences (XBIO) entered into a securities purchase agreement with several institutional and accredited investors providing for the purchase and sale of ~2.45M shares of the Company's common stock at a purchase price of $2.45 per share, in a registered direct offering priced at-the-...
FRAMINGHAM, MA / ACCESSWIRE / December 10, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, a...
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...
Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI)&...
Nano-cap Xenetic Biosciences (XBIO) surges 255% in premarket, in reaction to positive Phase 3 data reported by its partner, PJSC Pharmsynthez, evaluating Epolong that utilizes the company's PolyXen, for the treatment of anemia in patients with chronic kidney disease ((CKD)...
Xenetic leverages its proprietary drug delivery platform, PolyXen, through partnerships with biotechnology and pharmaceutical companies to improve the half-life and other pharmacological properties of next-generation biologic drugs Epolong, a polysialylated form of recombinant human er...
Sunesis Pharmaceuticals (SNSS) +50% after announcing merger agreement with Viracta Therapeutics.China Automotive Systems (CAAS) +32% on guiding 2021 sales boom.India Globalization Capital (IGC) +24%.Ameri Holdings (AMRH) +26%.Oramed Pharmaceuticals (ORMP) +24%.Navios ...
- Continued Advancement of XCART™ Platform Towards an IND Filing and Phase 1 Study - Leveraging Partnerships With Leading Global Academic Institutions, Including Scripps Research FRAMINGHAM, MA / ACCESSWIRE / November 13, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (...
- Live video webcast with CEO, Jeffrey Eisenberg, on Tuesday, November 12 th at 8:00 AM EST - FRAMINGHAM, MA / ACCESSWIRE / November 5, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a p...
Strongbridge Biopharma (NASDAQ: SBBP ) -16% after pricing $25M share offering. More news on: Strongbridge Biopharma plc, NuCana plc, Dave & Buster's Entertainment, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...